

*Variant: NM\_000546.5(TP53):c.353C>T (p.Thr118Ile)*

Version: 2.0

CA16620635 [↗](#)

419837 (ClinVar) [↗](#)

**Gene:** TP53 ([HGNC:7157](#))

**Condition:** Li-Fraumeni syndrome ([MONDO:0018875](#))

**Inheritance Mode:** Autosomal dominant inheritance

**UUID:** fc7cc0ba-f84e-46c8-acb3-ef170d24b394

**Approved on:** 2025-03-04

**Published on:** 2025-06-23

### *HGVS expressions*

**NM\_000546.5:c.353C>T**

NM\_000546.5(TP53):c.353C>T (p.Thr118Ile)

NC\_000017.11:g.7676016G>A

CM000679.2:g.7676016G>A

NC\_000017.10:g.7579334G>A

CM000679.1:g.7579334G>A

NC\_000017.9:g.7520059G>A

NG\_017013.2:g.16535C>T

ENST00000503591.2:c.353C>T

ENST00000508793.6:c.353C>T

ENST00000509690.6:c.-21-780C>T

ENST00000514944.6:c.96+366C>T

ENST00000604348.6:c.353C>T

ENST00000269305.9:c.353C>T

ENST00000269305.8:c.353C>T

ENST00000359597.8:c.353C>T

ENST00000413465.6:c.353C>T

ENST00000420246.6:c.353C>T

ENST00000445888.6:c.353C>T

ENST00000455263.6:c.353C>T

ENST00000503591.1:c.353C>T

ENST00000505014.5:n.609C>T

ENST00000508793.5:c.353C>T

ENST00000509690.5:c.-21-780C>T

ENST00000514944.5:c.96+366C>T

ENST00000604348.5:c.353C>T

ENST00000610292.4:c.236C>T

ENST00000610538.4:c.236C>T

ENST00000615910.4:c.340+9C>T

ENST00000617185.4:c.353C>T

ENST00000619485.4:c.236C>T

ENST00000620739.4:c.236C>T

ENST00000622645.4:c.236C>T

ENST00000635293.1:c.236C>T

NM\_001126112.2:c.353C>T

NM\_001126113.2:c.353C>T

NM\_001126114.2:c.353C>T

NM\_001126118.1:c.236C>T  
NM\_001276695.1:c.236C>T  
NM\_001276696.1:c.236C>T  
NM\_001276760.1:c.236C>T  
NM\_001276761.1:c.236C>T  
NM\_001276695.2:c.236C>T  
NM\_001276696.2:c.236C>T  
NM\_001276760.2:c.236C>T  
NM\_001276761.2:c.236C>T  
NM\_000546.6:c.353C>T  
NM\_001126112.3:c.353C>T  
NM\_001126113.3:c.353C>T  
NM\_001126114.3:c.353C>T  
NM\_001126118.2:c.236C>T  
NM\_001276695.3:c.236C>T  
NM\_001276696.3:c.236C>T  
NM\_001276760.3:c.236C>T  
NM\_001276761.3:c.236C>T

Likely Benign

Met criteria codes **4**

BS2\_Supporting PM2\_Supporting  
PP3\_Moderate BS3

Not Met criteria codes **11**

PS1 PS2 PS3 BA1 PP1  
PM1 PM6 BS1 BS4 BP4  
BP2

Evidence Links **3**

Expert Panel

TP53 VCEP [↗](#)

Criteria Specification Information

[↗](#) **Criteria Specification:** *ClinGen TP53 Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for TP53 Version 2.3.0*

[↗](#) **Criteria Specification Approval History**









[↗](#) **Criteria Specifications for this VCEP**

Evidence submitted by expert panel

### TP53 VCEP

The NM\_000546.6: c.353C>T variant in TP53 is a missense variant predicted to cause substitution of threonine by isoleucine at amino acid 118 (p.Thr118Ile). This variant has been observed in 2-3 heterozygous unrelated females from the same data source with no personal history of cancer prior to age 60 years and no personal history of sarcoma at any age (BS2\_Supporting; ClinVar SCVs: SCV000664386.6). This variant has an allele frequency of 0.0000006203 (1/1612196 alleles) across gnomAD v4.1.0 which is lower than the ClinGen TP53 VCEP threshold (<0.00003) for PM2\_Supporting and has no more than one allele per non-bottleneck subpopulation (PM2\_Supporting). In vitro assays performed in yeast and/or human cell lines showed functional transactivation and retained growth suppression activity indicating that this variant does not impact protein function (BS3; PMIDs: 12826609, 29979965, 30224644). Computational predictor scores (BayesDel = 0.3466; Align GVGD = Class 65) are above recommended thresholds (BayesDel > 0.16 and an Align GVGD Class of 65), evidence that correlates with impact to TP53 via protein change (PP3\_Moderate). In summary, this variant meets the criteria to be classified as likely benign for Li Fraumeni syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen TP53 VCEP: BS2\_Supporting, PM2\_Supporting, BS3, PP3\_Moderate. (Bayesian Points: -2; VCEP specifications version 2.3).

Met criteria codes
















<b>BS2_Supporting</b>			This variant has been observed in 2-3 heterozygous unrelated females from the same data source with no personal history of cancer prior to age 60 years and no personal history of sarcoma at any age (BS2_Supporting; ClinVar SCVs: SCV000664386.6).
<b>PM2_Supporting</b>			This variant has an allele frequency of 0.0000006203 (1/1612196 alleles) across gnomAD v4.1.0 which is lower than the Clingen TP53 VCEP threshold (<0.00003) for PM2_Supporting and has no more than one allele per non-bottleneck subpopulation (PM2_Supporting).
<b>PP3_Moderate</b>			Computational predictor scores (BayesDel = 0.3466; Align GVGD = Class 65) are above recommended thresholds (BayesDel > 0.16 and an Align GVGD Class of 65), evidence that correlates with impact to TP53 via protein change (PP3_Moderate).
<b>BS3</b>			In vitro assays performed in yeast and/or human cell lines showed functional transactivation and retained growth suppression activity indicating that this variant does not impact protein function(BS3; PMIDs: 12826609, 29979965, 30224644).






noLOF/noDNE [PubMed:30224644](#) 

noLOF [PubMed:29979965](#) 

Functional [PubMed:12826609](#) 

#### Not Met criteria codes

<b>PS1</b>			No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
<b>PS2</b>			No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
<b>PS3</b>			No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
<b>BA1</b>			Absent in gnomAD v2.1.1 (non-cancer)
<b>PP1</b>			No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
<b>PM1</b>			This variant does not reside within a region of TP53 that is defined as a mutational hotspot by the ClinGen TP53 VCEP (PM1 not met).
<b>PM6</b>			No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
<b>BS1</b>			Absent in gnomAD v2.1.1 (non-cancer)

<b>BS4</b>	 	No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
<b>BP4</b>	 	No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
<b>BP2</b>		No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline

Curation History [↗](#)

Showing 1 to 2 of 2 rows

--

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.